National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Delstrigo® is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir



NCPE Assessment Process Complete
Rapid review commissioned 06/12/2018
Rapid review completed 16/01/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that Destrigo® be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

The HSE has approved reimbursement; February 2019